CN104688716B - 一种盐酸氯卡色林缓释胶囊及其制备方法 - Google Patents
一种盐酸氯卡色林缓释胶囊及其制备方法 Download PDFInfo
- Publication number
- CN104688716B CN104688716B CN201510071244.3A CN201510071244A CN104688716B CN 104688716 B CN104688716 B CN 104688716B CN 201510071244 A CN201510071244 A CN 201510071244A CN 104688716 B CN104688716 B CN 104688716B
- Authority
- CN
- China
- Prior art keywords
- hydrochloric acid
- acid lorcaserin
- lorcaserin
- release layer
- spansule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 142
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 title claims abstract description 70
- 229960005060 lorcaserin Drugs 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000008188 pellet Substances 0.000 claims abstract description 31
- 238000013268 sustained release Methods 0.000 claims abstract description 22
- 239000012730 sustained-release form Substances 0.000 claims abstract description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 16
- 229930006000 Sucrose Natural products 0.000 claims abstract description 16
- 229960004793 sucrose Drugs 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 14
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 9
- 229920002472 Starch Polymers 0.000 claims abstract description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 9
- 239000008107 starch Substances 0.000 claims abstract description 9
- 235000019698 starch Nutrition 0.000 claims abstract description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 229920003137 Eudragit® S polymer Polymers 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 22
- 239000006187 pill Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000006188 syrup Substances 0.000 claims description 9
- 235000020357 syrup Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000011122 softwood Substances 0.000 claims description 7
- 238000001125 extrusion Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229920003141 Eudragit® S 100 Polymers 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 239000004744 fabric Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 238000005096 rolling process Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003643 water by type Substances 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 3
- 235000021050 feed intake Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000003801 milling Methods 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 235000012222 talc Nutrition 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 235000010603 pastilles Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 101100152794 Caenorhabditis elegans dpl-1 gene Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CBWUNQZJGJFJLZ-UHFFFAOYSA-N [Cl].Cl Chemical compound [Cl].Cl CBWUNQZJGJFJLZ-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940120049 belviq Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071244.3A CN104688716B (zh) | 2015-02-11 | 2015-02-11 | 一种盐酸氯卡色林缓释胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071244.3A CN104688716B (zh) | 2015-02-11 | 2015-02-11 | 一种盐酸氯卡色林缓释胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104688716A CN104688716A (zh) | 2015-06-10 |
CN104688716B true CN104688716B (zh) | 2017-10-31 |
Family
ID=53336548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510071244.3A Active CN104688716B (zh) | 2015-02-11 | 2015-02-11 | 一种盐酸氯卡色林缓释胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104688716B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106880648B (zh) * | 2015-12-16 | 2021-07-09 | 深圳翰宇药业股份有限公司 | 一种药物组合物及其制备方法 |
CN106389377A (zh) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | 一种盐酸绿卡色林胶囊及其制备工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102274205A (zh) * | 2011-07-21 | 2011-12-14 | 佛山市隆信医药科技有限公司 | 琥珀酸美托洛尔的缓释胶囊及制备方法 |
CN103316026A (zh) * | 2012-03-23 | 2013-09-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
-
2015
- 2015-02-11 CN CN201510071244.3A patent/CN104688716B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102274205A (zh) * | 2011-07-21 | 2011-12-14 | 佛山市隆信医药科技有限公司 | 琥珀酸美托洛尔的缓释胶囊及制备方法 |
CN103316026A (zh) * | 2012-03-23 | 2013-09-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
Non-Patent Citations (1)
Title |
---|
"Lorcaserin for weight management";James R Taylor, et al.;《Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy》;20130612(第6期);第209-216页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104688716A (zh) | 2015-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108289835A (zh) | 修饰释放口服给药的氨基酸制剂 | |
CN105832691A (zh) | 一种度拉糖肽结肠定位缓释制剂及其制备方法 | |
CN105456223B (zh) | 美沙拉秦缓释微丸及其制备方法和美沙拉秦缓释胶囊 | |
CN104688716B (zh) | 一种盐酸氯卡色林缓释胶囊及其制备方法 | |
CN107308127A (zh) | 双氯芬酸钠多单元缓释微丸片 | |
CN110075082A (zh) | 一种恩诺沙星速释微丸及其制备方法 | |
CN104906160B (zh) | 一种灯盏细辛提取物的肠溶制剂 | |
CN102755310B (zh) | 一种含有左旋多巴的组合物药物制剂 | |
CN103417483B (zh) | 盐酸美金刚缓释干混悬剂及其制备方法 | |
CN106806353B (zh) | 艾拉莫德缓释胶囊及其制备方法 | |
CN109394722A (zh) | 普罗帕酮微片、包含该微片的多单元剂型及其制备方法和用途 | |
CN101658507B (zh) | 一种愈创木酚甘油醚和伪麻黄碱的复方缓释制剂 | |
CN106344519B (zh) | 一种坦度螺酮肠溶微丸及其制备方法和用途 | |
CN103393608A (zh) | 一种新利司他微丸及其制备方法 | |
CN1985823A (zh) | 一种含有盐酸二甲双胍罗格列酮的缓释制剂及其制备方法 | |
CN109528706A (zh) | 一种用于治疗糖尿病的药物组合物及其制备方法和用途 | |
CN101756981A (zh) | 一种布洛氯雷伪麻缓释制剂及其制备方法 | |
CN106309396A (zh) | 一种沃拉帕沙制剂的制备方法 | |
CN103948552A (zh) | 一种奥卡西平控释片及其制备方法 | |
CN101455679A (zh) | 一种阿胶微丸及其制备方法 | |
CN100525770C (zh) | 一种含茶碱和沙丁胺醇活性组分的口服复方缓释制剂及制备工艺 | |
CN104147012B (zh) | 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂 | |
CN114762684B (zh) | 一种治疗帕金森的缓释胶囊及其制备方法 | |
CN112451511B (zh) | 一种盐酸二甲双胍制剂及其制备方法 | |
CN108096207A (zh) | 一种罗他夫辛肠溶片的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 430000 room 01, 17 / F, building 11, phase 3.2, Wuhan Optical Valley International Biomedical enterprise accelerator, No. 388, Gaoxin Second Road, Donghu New Technology Development Zone, Wuhan, Hubei Province (Wuhan area of free trade zone) Patentee after: Wuhan Runxin Technology Co.,Ltd. Country or region after: China Address before: Room D111, 4th Floor, Building B4, Biocity, No. 666 Gaoxin Avenue, Hongshan District, Wuhan City, Hubei Province, 430075 Patentee before: WUHAN RUNXIN TECHNOLOGY CO.,LTD. Country or region before: China |